EP0000828A1 - Synthetische beta-Lactam Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneipräparate - Google Patents
Synthetische beta-Lactam Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneipräparate Download PDFInfo
- Publication number
- EP0000828A1 EP0000828A1 EP78300231A EP78300231A EP0000828A1 EP 0000828 A1 EP0000828 A1 EP 0000828A1 EP 78300231 A EP78300231 A EP 78300231A EP 78300231 A EP78300231 A EP 78300231A EP 0000828 A1 EP0000828 A1 EP 0000828A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- ene
- hept
- carboxylate
- oxo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 20
- -1 beta-lactam compounds Chemical class 0.000 title claims description 36
- 239000000203 mixture Substances 0.000 title description 34
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 150000003839 salts Chemical group 0.000 claims abstract description 26
- 150000002148 esters Chemical group 0.000 claims abstract description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 9
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 9
- 239000000460 chlorine Substances 0.000 claims abstract description 9
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 9
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 9
- 239000011737 fluorine Substances 0.000 claims abstract description 9
- 125000002843 carboxylic acid group Chemical group 0.000 claims abstract description 4
- 125000006502 nitrobenzyl group Chemical group 0.000 claims abstract description 4
- 125000006278 bromobenzyl group Chemical group 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- 125000004803 chlorobenzyl group Chemical group 0.000 claims abstract description 3
- 125000004175 fluorobenzyl group Chemical group 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims description 27
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 125000005633 phthalidyl group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 125000004185 ester group Chemical group 0.000 claims description 7
- 150000001734 carboxylic acid salts Chemical class 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229910052700 potassium Chemical group 0.000 claims description 4
- 239000011591 potassium Chemical group 0.000 claims description 4
- LPCNCFWQKRMRGZ-UHFFFAOYSA-N (4-nitrophenyl)methyl 7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)C1=C(SC=2C=CC=CC=2)CC2N1C(=O)C2 LPCNCFWQKRMRGZ-UHFFFAOYSA-N 0.000 claims description 3
- 241000282414 Homo sapiens Species 0.000 claims description 3
- MBWMHGALCITXCZ-UHFFFAOYSA-N benzyl 3-(4-acetamidophenyl)sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1=CC(NC(=O)C)=CC=C1SC1=C(C(=O)OCC=2C=CC=CC=2)N2C(=O)CC2C1 MBWMHGALCITXCZ-UHFFFAOYSA-N 0.000 claims description 3
- AKTMKWAUPOWVDV-UHFFFAOYSA-N benzyl 3-(4-nitrophenyl)sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1SC1=C(C(=O)OCC=2C=CC=CC=2)N2C(=O)CC2C1 AKTMKWAUPOWVDV-UHFFFAOYSA-N 0.000 claims description 3
- YFVCJUUZVZGMPJ-UHFFFAOYSA-N benzyl 7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1C=CC=CC=1SC=1CC2CC(=O)N2C=1C(=O)OCC1=CC=CC=C1 YFVCJUUZVZGMPJ-UHFFFAOYSA-N 0.000 claims description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- WKCVZNDNNMOAQT-UHFFFAOYSA-N methyl 7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1C2CC(=O)N2C(C(=O)OC)=C1SC1=CC=CC=C1 WKCVZNDNNMOAQT-UHFFFAOYSA-N 0.000 claims description 3
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- NEQGRZCWHVYPKT-UHFFFAOYSA-N tert-butyl 3-(4-nitrophenyl)sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1C2CC(=O)N2C(C(=O)OC(C)(C)C)=C1SC1=CC=C([N+]([O-])=O)C=C1 NEQGRZCWHVYPKT-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- XGDJBVMCOWHQIZ-UHFFFAOYSA-M sodium;7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound [Na+].C1C2CC(=O)N2C(C(=O)[O-])=C1SC1=CC=CC=C1 XGDJBVMCOWHQIZ-UHFFFAOYSA-M 0.000 claims description 2
- IPAZULNDVWNOCR-UHFFFAOYSA-N tert-butyl 7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1C2CC(=O)N2C(C(=O)OC(C)(C)C)=C1SC1=CC=CC=C1 IPAZULNDVWNOCR-UHFFFAOYSA-N 0.000 claims description 2
- HZJLONFYZUQTFH-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 7-oxo-3-phenyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1C2CC(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C1C1=CC=CC=C1 HZJLONFYZUQTFH-UHFFFAOYSA-N 0.000 claims 1
- QUZYJLGCWCHKGO-UHFFFAOYSA-N benzyl 3-(3-aminophenyl)sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound NC1=CC=CC(SC=2CC3N(C(C3)=O)C=2C(=O)OCC=2C=CC=CC=2)=C1 QUZYJLGCWCHKGO-UHFFFAOYSA-N 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 151
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 75
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 72
- 239000000243 solution Substances 0.000 description 63
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 62
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 61
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 32
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 31
- 229910052786 argon Inorganic materials 0.000 description 31
- 239000007787 solid Substances 0.000 description 31
- 239000002904 solvent Substances 0.000 description 30
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000004587 chromatography analysis Methods 0.000 description 14
- 229940073584 methylene chloride Drugs 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- 238000010828 elution Methods 0.000 description 10
- 239000006260 foam Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- ZLUSCZLCHQSJRU-UHFFFAOYSA-N thallium(1+) Chemical group [Tl+] ZLUSCZLCHQSJRU-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000001665 trituration Methods 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 238000007327 hydrogenolysis reaction Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 150000007970 thio esters Chemical class 0.000 description 5
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 0 CC(CC(C1)(C1(C(O*)=O)N)S*)CC(C)=O Chemical compound CC(CC(C1)(C1(C(O*)=O)N)S*)CC(C)=O 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- BUUDWHIBUGYSBJ-UHFFFAOYSA-N 2,2-dimethylpropanoyloxymethyl 7-oxo-3-phenylsulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1C2CC(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C1SC1=CC=CC=C1 BUUDWHIBUGYSBJ-UHFFFAOYSA-N 0.000 description 2
- PKRHOIOVOBITKL-UHFFFAOYSA-N 2,3-dimethylpyridine;hydrochloride Chemical compound Cl.CC1=CC=CN=C1C PKRHOIOVOBITKL-UHFFFAOYSA-N 0.000 description 2
- CLMSHAWYULIVFQ-UHFFFAOYSA-N 3-bromo-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(Br)OC(=O)C2=C1 CLMSHAWYULIVFQ-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- RNKLLZTVWHLOJG-UHFFFAOYSA-N 4-prop-2-enylazetidin-2-one Chemical compound C=CCC1CC(=O)N1 RNKLLZTVWHLOJG-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- SWTVPHKYKAKNEJ-UHFFFAOYSA-N benzyl 3-(4-aminophenyl)sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1=CC(N)=CC=C1SC1=C(C(=O)OCC=2C=CC=CC=2)N2C(=O)CC2C1 SWTVPHKYKAKNEJ-UHFFFAOYSA-N 0.000 description 2
- JPYVGCCGIBQCBT-UHFFFAOYSA-N benzyl 3-[4-[(4-nitrophenyl)methoxycarbonylamino]phenyl]sulfanyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)NC(C=C1)=CC=C1SC1=C(C(=O)OCC=2C=CC=CC=2)N2C(=O)CC2C1 JPYVGCCGIBQCBT-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- SFIBCACOCIDDSC-UHFFFAOYSA-N (4-nitrophenyl)methyl 2-[2-(benzenecarbonothioyl)-4-oxoazetidin-1-yl]-2-(triphenyl-lambda5-phosphanylidene)acetate Chemical compound C1=CC([N+](=O)[O-])=CC=C1COC(=O)C(N1C(CC1C(=S)C=1C=CC=CC=1)=O)=P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 SFIBCACOCIDDSC-UHFFFAOYSA-N 0.000 description 1
- OIHLWKOVIJPVHC-UHFFFAOYSA-N (4-nitrophenyl)methyl 2-oxoacetate;hydrate Chemical compound O.[O-][N+](=O)C1=CC=C(COC(=O)C=O)C=C1 OIHLWKOVIJPVHC-UHFFFAOYSA-N 0.000 description 1
- MHSGOABISYIYKP-UHFFFAOYSA-N (4-nitrophenyl)methyl carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(COC(Cl)=O)C=C1 MHSGOABISYIYKP-UHFFFAOYSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- PVUZSIUMITWALP-UHFFFAOYSA-N 2-[1-[2-[(4-nitrophenyl)methoxy]-2-oxo-1-(triphenyl-$l^{5}-phosphanylidene)ethyl]-4-oxoazetidin-2-yl]acetic acid Chemical compound OC(=O)CC1CC(=O)N1C(C(=O)OCC=1C=CC(=CC=1)[N+]([O-])=O)=P(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PVUZSIUMITWALP-UHFFFAOYSA-N 0.000 description 1
- BWSQKOKULIALEW-UHFFFAOYSA-N 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[2-(piperidin-3-ylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound FC1=C(C=C(C=C1)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NC1CNCCC1)C(F)(F)F BWSQKOKULIALEW-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical compound NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- AXBVSRMHOPMXBA-UHFFFAOYSA-N 4-nitrothiophenol Chemical compound [O-][N+](=O)C1=CC=C(S)C=C1 AXBVSRMHOPMXBA-UHFFFAOYSA-N 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- DTEHBWOLFMUUSI-UHFFFAOYSA-N CC(CC1NC(C)=[P](c2ccccc2)(c2ccccc2)(c2ccccc2)=CC1)=O Chemical compound CC(CC1NC(C)=[P](c2ccccc2)(c2ccccc2)(c2ccccc2)=CC1)=O DTEHBWOLFMUUSI-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229910021213 Co2C Inorganic materials 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N Glyoxylic acid Natural products OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GTLWLYABGGVYTD-UHFFFAOYSA-N NC1=CC=C(C=C1)C(=S)CC1CC(N1C(=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)=O Chemical compound NC1=CC=C(C=C1)C(=S)CC1CC(N1C(=P(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)C(=O)OCC1=CC=CC=C1)=O GTLWLYABGGVYTD-UHFFFAOYSA-N 0.000 description 1
- 229910003202 NH4 Inorganic materials 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 241000218589 Streptomyces olivaceus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- WLOCMJQMRCPVRH-UHFFFAOYSA-N benzyl 2-oxoacetate;hydrate Chemical compound O.O=CC(=O)OCC1=CC=CC=C1 WLOCMJQMRCPVRH-UHFFFAOYSA-N 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ACBDNFPUXYGKPT-UHFFFAOYSA-N bromomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCBr ACBDNFPUXYGKPT-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000003226 decolorizating effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZJULYDCRWUEPTK-UHFFFAOYSA-N dichloromethyl Chemical compound Cl[CH]Cl ZJULYDCRWUEPTK-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- YCYZHZKXVZOANE-UHFFFAOYSA-N methyl 2-oxoacetate;hydrate Chemical compound O.COC(=O)C=O YCYZHZKXVZOANE-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- MOOYVEVEDVVKGD-UHFFFAOYSA-N oxaldehydic acid;hydrate Chemical compound O.OC(=O)C=O MOOYVEVEDVVKGD-UHFFFAOYSA-N 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- QYZLKGVUSQXAMU-UHFFFAOYSA-N penta-1,4-diene Chemical compound C=CCC=C QYZLKGVUSQXAMU-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- PYKYQLRSHLIABH-UHFFFAOYSA-N tert-butyl 2-oxoacetate;hydrate Chemical compound O.CC(C)(C)OC(=O)C=O PYKYQLRSHLIABH-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
- C07D477/20—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/568—Four-membered rings
Definitions
- the present invention relates to ⁇ -lactam antibacterials, to a process for their preparation and to compositions containing them.
- An apt group of compounds within formula (II) includes those wherein:
- a further apt group of compounds within formula (II) includes those wherein:
- Suitable esterifying groups R 1 include alkyl groups of up to 12 carbon atoms, alkenyl groups of up to 12 carbon atoms, alkynyl groups of up to 12 carbon atoms, phenyl or benzyl groups or any of the aforesaid inertly substituted by lower alkoxyl, lower acyloxyl,halogen, nitro or the like.group. Used herein 'inertly substituted' means that the resulting group is stable and will not undergo rapid decomposition.
- Particularly suitable esterifying groups R 1 include lower alkyl groups optionally substituted by lower alkoxyl, the benzyl group optionally substituted by lower alkoxyl, nitro, chloro or the like,and those groups which are known to give rise to rapid in-vivo hydrolysis in penicillin esters.
- Certain preferred esterifying groups R 1 include methyl, ethyl, methoxymethyl, 2-methoxyethyl, benzyl, methoxybenzyl, nitrobenzyl and the like.
- esterifying groups R 1 include those which give rise to in-vivo hydrolysable esters such as acetoxymethyl, pivaloyloxymethyl, ⁇ -ethoxycarbonyloxyethyl, phthalidyl and the like.
- a preferred group R 1 of those giving rise to in-vivo hydrolysable esters is the phthalidyl group.
- Preferred groups R 1 are those such that CO 2 R 1 is a carboxylic acid salt.
- the group C0 2 R 10 may also be a carboxylic acid salt.
- CO 2 R 1 is a carboxylic acid salt in compounds of the formula (II) also containing the group CO 2 R 10
- C0 2 R 10 is usually also a carboxylic acid salt, and normally R 1 and R 10 are like cations.
- salts of compounds of formula (II) are conventional pharmaceutically acceptable salts such as the alkali metal and alkaline earth metal salts, in particular the sodium, potassium, calcium and magnesium salts; ammonium and substituted ammonium salts, for example the t-butylamine salt.
- Particularly suitable salts are the potassium and sodium salts, especially the sodium salts.
- R 2 is a phenyl group, optionally mono-substituted.
- Suitable groups R 2 include the phenyl, p-chlorophenyl, m-chlorophenyl, p-nitrophenyl, m-nitrophenyl, p-ethoxy- carbonylphenyl, p-fluorophenyl, p-methylphenyl, p-aminophenyl, p-acetamidophenyl, p-(4'-nitrobenzyloxycarbonyl- amino)phenyl, p-methoxyphenyl and like groups.
- a preferred sub-group of compounds within formula (II) is of formula (IV): wherein:
- R 1 1 include acetoxymethyl, pivaloyloxymethyl, ⁇ -ethoxycarbonyloxyethyl, phthalidyl and the like.
- R 1 1 is preferably phthalidyl.
- Suitable groups R 2 are as so described under formula (II).
- a second preferred sub-group of compounds within formula (II) is of formula (V): wherein:
- Particularly suitable salts are the potassium and sodium salts, especially the sodium salts.
- Suitable groups R 2 are as so described under formula (II).
- a sub-group of compounds within formula (II) of interest is of formula (VI): wherein:
- a suitable group R 3 1 is tert-butyl.
- Another suitable group R 3 1 is methyl.
- An additional suitable group R 3 1 is benzyl.
- a suitable group R 3 1 is p-nitrobenzyl.
- One more suitable group R 3 1 is phthalidyl.
- a further suitable group R 3 1 is pivaloyloxymethyl.
- R 3 1 is sodium.
- p-Nitrobenzyl is a preferred group R 3 1 .
- Phthalidyl is also a preferred group R 3 1 .
- Sodium is another preferred group R 3 1 .
- a suitable group R 1 2 is p-acetamidophenyl.
- R 1 2 is phenyl
- a suitable group R 1 2 is p-nitrophenyl.
- One more suitable group R 2 is p-aminophenyl.
- a further suitable group R 1 2 is p-(4'-nitrobenzyloxy- carbonylamino)phenyl.
- a reaction sequence leading to the compounds of this invention is as follows:
- R 4 , R 5 and R 6 are each phenyl groups.
- the ring closure is normally brought about by heating the compound of the formula (VII) in an inert solvent; for example temperatures of 90-120°C and more suitably 100-110°C may be employed in a solvent such as toluene or the like.
- the reaction is best carried out under dry conditions under an inert gas.
- the ester of the compound (II) produced may be isolated by any standard method such as fractional crystal - lisation or chromatography. We have found that it is most convenient to separate the desired product by column chromatography.
- the ester employed is preferably one which is readily converted to the parent acid or its salt by mild methods of hydrogenolysis.
- the invention includes a process for preparing a salt or free acid of a compound (II) which process comprises de-esterifying an ester of a compound of formula (II).
- Particularly suitable esters for use in this process include benzyl esters, optionally substituted in the para position by a lower alkoxy, or nitro group or a halogen atom.
- a preferred ester for use in this process is the p-nitrobenzyl ester.
- Esters of compounds (II) may be de-esterified by conventional methods of hydrogenolysis.
- Suitable methods include hydrogenation in the presence of a transition metal catalyst.
- the pressure of hydrogen used in the reaction may be low, medium or high but in general an approximately atmospheric or slightly superatmospheric pressure of hydrogen is preferred.
- the transition metal catalyst employed is preferably palladium on charcoal or on calcium carbonate.
- the hydrogenation maybe effected in a suitable solvent in which the ester is soluble such as aqueous dioxan or the like. If this hydrogenation is carried out in the presence of a base then a salt of compounds (II) is produced.
- Suitable bases for inclusion include NaHC0 3 , KHC0 3 , Na 2 C0 3 , K 2 CO 3 , CaC0 3 , MgCO 3 , LiHCO 3 , NH 4 OCOCH 3 and the like.
- Suitable bases which may be used to neutralise acids within formula (II) include LiOH, NaOH, NaHCO 3 , KOH, Ca(OH) 2 and Ba(OH) 2 .
- the salts of acids (II) may be converted to esters in conventional manner, for example by reaction with a reactive halide such as bromophthalide in solution in dimethylformamide or like solvent.
- a reactive halide such as bromophthalide in solution in dimethylformamide or like solvent.
- the substituent group or groups within the group R 2 in the compounds of formula (II) may be varied by conventional reactions.
- a substituent when a substituent is a nitro group it may be reduced in a conventional manner to an amino group, for example by catalysed hydrogenation.
- an amino group may be acylated to give a substituted amido group, for example by treatment with an acyl halide in the presence of an organic base.
- Substituents NHC0 2 R3 where R 3 is a benzyl group substituted as hereinbefore described may be converted to amino groups, for example by hydrogenolysis.
- the compound of the formula (VII) may be prepared by the reaction of a corresponding compound of the formula (VIII): wherein R 4 , R 5 and R 6 are as defined in relation to formula (VII) with a diloweralkylphosphorochloridate and a triloweralkylamine followed by reaction with a derivative of the formula (IX): where L 0 is a sodium or thallium (I) cation or an ammonium ion substituted by up to three organic groups, and R 2 is as defined in relation to formula (II).
- L 0 is a substituted ammonium ion, it is preferably a tertiary ammonium ion, such as the triethylammonium ion. It is conveniently generated in situ by the reaction of a compound of the formula HSR 2 with an amine, preferably a tertiary amine.
- L ⁇ is a thallium (I) cation.
- L ⁇ is a sodium cation.
- a particularly suitable diloweralkylphosphorochloridate is uiethylphosphorochloridate.
- a particularly suitable triloweralkylamine is triethylamine.
- the reaction is generally carried out in an inert organic solvent such as tetrahydrofuran at a non-extreme temperature such as 0 to 40°C, for example 15-25°C.
- an inert organic solvent such as tetrahydrofuran at a non-extreme temperature such as 0 to 40°C, for example 15-25°C.
- the compound of the formula (VIII) may be prepared by the reaction of the compound of the formula (X): wherein R 4 1 , R 4 , R 5 and R 6 are as defined in relation to formula (VIII) with ozone in the presence of trifluoroacetic acid followed by m-chloroperbenzoic acid.
- the ozonolysis is generally performed at a depressed temperature such as -40 to -80°C, for example about -70°C and in solution in an inert solvent such as methylene chloride. Excess ozone is removed by flushing with an inert gas and thereafter a solution of the peracid is added to the reaction mixture.
- the compound of the formula (X) may be prepared from the corresponding compound of the formula (XI): wherein R 4 1 is as defined in relation to formula (X) with a phosphine of the formula (XII): where R 4 , R 5 and R 6 are as defined in relation to formula (X).
- This reaction is normally effected in the presence of at least one equivalent of a base of relatively low nucleophilicity such as 2,6-lutidine at an ambient temperature in a dry solvent such as dioxan, tetrahydrofuran or the like.
- a base of relatively low nucleophilicity such as 2,6-lutidine
- the compound of the formula (XI) may be prepared from the corresponding carbinol of the formula (XIII): wherein R 4 1 is as defined in relation to formula (XI) by reaction with thionyl chloride.
- This reaction is also normally effected in the presence of at least one equivalent of a base of relatively low nucleophilicity in a dry solvent such as dioxan or tetrahydrofuran but in this instance the reaction is performed at a depressed temperature, for example -30 to -10°C.
- the preceding carbinol may be prepared by the reaction of a compound of the formula (XIV): with a glyoxylic acid ester of the formula (XV): wherein R 4 1 is as defined in relation to formula (VII).
- this reaction is carried out in an inert solvent at an elevated temperature, for example in dry benzene under reflux.
- the compound of the formula (XIV) may be prepared as described in Description 1 hereinafter.
- the present invention provides the compounds of the formulae (VII) and (VIII), as useful intermediates.
- the process for the preparation of these compounds also forms part of this invention.
- the present invention also provides a pharmaceutical composition which comprises a compound of the formula (II) as hereinbefore defined and a pharmaceutically acceptable carrier.
- composition of the invention includes those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in domestic animals or humans.
- compositions of this invention include tablets, capsules, creams, syrups, suspensions, solutions, reconstitutable powders and sterile forms suitable for injection or infusion.
- Such compositions may contain conventional pharmaceutically acceptable materials such as diluents, binders, colours, flavours, preservatives, disintegrants and the like in accordance with conventional pharmaceutical practice in the manner well understood by those skilled in the art of formulating antibacterial agents.
- the compound of the formula (II) present in such compositions will be in-vivo hydrolysable to the parent acid or its salt.
- composition of this invention may beneficially also comprise a penicillin or cephalosporin.
- penicillins for use in these compositions include amoxycillin trihydrate and sodium amoxycillin.
- the present invention also provides a method of treatment and/or prophylaxis of bacterial infections in human beings or domestic animals, which method comprises the administration to the sufferer of an effective amount of a compound of the formula (II).
- 1,4 Pentadiene(d1) (30g) and chlorosulphonyl isocyanate (d2)(35.4 ml) were mixed and allowed to stand at room temperature for 3 days, in a pressure bottle.
- the thick, dark syrup obtained was diluted with methylene chloride (500ml) and added dropwise to a stirred solution of sodium sulphite (66g) in water (240ml).
- the chloride (d 14) was dissolved in dry dioxane (80 ml) and treated with triphenylphosphine (8.2 g) and 2,6-lutidine (3.7 ml). The reaction mixture was stirred overnight and then filtered; the filtrate concentrated and re-dissolved in ethyl acetate (100 ml). This solution was washed free of base with N/10 hydrochloric acid (ca 100 ml) and then washed with brine and dried over sodium sulphate. The solution was concentrated and then chromatographed on silica gel 60 ( ⁇ 230 mesh) eluting with ethyl acetate/60-80° petroleum ether 7:3 to give a foam.
- the acid (2a) was further characterised by treatment with benzyl bromide and potassium carbonate in dimethylformamida: to give the benzyl ester (2b), obtained as white crystals (ex ether) m. p . 176.5-178°C. ⁇ max (CHCl 3 ) 1735 , 16 4 0 , 1610 cm -1 . (Found: C, 72.20; H, 6.59; N, 2.28; C 36 H 36 NO 5 P re- quires C, 72.83; H, 6.11; N, 2.36%).
- the acid (2a) (754mg; 1.5 mmol) was dissolved in dry THF (15ml) containing Et 3 N (167m g ; 1.6 mmol) and stirred at RT.
- a solution of diethylphosphorochloridate (272mg; 1.6mmol) in THF (5ml) was added dropwise to the solution under argon. Stirring was continued for 3h.
- the solution was filtered, and to the solution was added thallium (I) phenylthiolate (500mg; 1.6 mmol). Stiring was continued overnight.
- This foam was taken up in dry methylene chloride (70ml), and stirred with basic alumina (8g), for 2 hours.
- the acid (8a) was characterised by treatment with benzyl bromide and potassium carbonate in dimethylformamide to give the benzyl ester (8b), as white crystals (ex ethyl acetate/petroleum ether), mp 146-8°C, ⁇ max (CHCl 3 ) 1740, 1620cm -1 (Found: C, 71.71; H, 5.67; N, 2.44. C 33 H 30 NO 5 P requires C, 71.87; H, 5.44: N, 2.54%.
- the phosphorane (13) (150mg) was refluxed in dry toluene (100ml) under argon for nine hours. The solvent was evaporated and the product chromatographed on Merck Kieselgel 60 using ethyl acetate/petol as eluant to yield the title compound (14) as the major product (25 mg ; 30%), ⁇ max (CHC13) 1790, 1705 cm -1 .
- the phosphorane (2.82g) in dry methylene chloride (125ml) was treated with trifluoroacetic acid (4ml) at 0°. The solution was cooled to -70° and treated with ozone until blue. Argon was passed through to remove excess ozone, and m-chloroperbenzoic acid (0.9g) in methylene chloride (20ml) was. added, and the mixture was stirred at RT overnight. The. solvent was evaporated, and the resulting white solid was dissolved in ethyl acetate and chromatographed on silica gel. Elution with 10% ethanol/ethyl acetate gave the product as the trifluoroacetic acid salt.
- the phosphorane (17) (550mg) was refluxed in dry toluene (500ml) for 24 hours with removal of water (Dean-Stark) under argon. The solvent was evaporated and the product chromatographed on florisil (200-300 U.S. mesh) using ethyl acetate/petrol (60-80°) as eluant to yield the title compound (52mg; 18%) as a crystalline solid from benzene/petrol (60-80°C) mp 112-4°C. ⁇ max (CHC1 3 ) 1 79 0, 1705 cm -1 .
- This thioester (19) was also prepared substituting the sodium thiolate mixture by solid thallium (I)p-acet- amidophenylthiolate. A comparable yield was obtained.
- the phosphorane (19) (136mg) was suspended in dry toluene (10ml) and the mixture was evaporated to dryness. The residue was suspended in dry toluene (60ml), and the mixture was degassed and heated, under argon, under reflux with a Dean-Stark head. After 5 hours the pale yellow solution was cooled to room temperature, and the solvent was evaporated. The residue was taken up in ethyl acetate (12ml), and-left overnight at 5°, when buff coloured crystals were obtained. These were collected (97.5mg) and shown by thin layer chromatography to be recovered starting material.
- the acid (12, prepared as in Example 4a) (1.675g) in dry tetrahydrofuran (80ml), under argon, was treated with triethylamine (0.472g) and diethylphosphorochloridate (0.807g). After stirring at room temperature for 3 hours the reaction mixture was added to freshly prepared sodium p-amino-phenylthiolate in tetrahydrofuran [prepared by treating p-aminophenylthiol (0.428g) in dry tetrahydrofuran (30ml)/hexamethylphosphoramide (0.505g), under argon at 0°, with sodium hydride (0.165g of a 50% suspension in oil)].
- the phosphorane (21) (0.461g) was taken up in dry toluene, and the mixture was evaporated to dryness.
- the residue was suspended in dry toluene (250ml), and the mixture was degassed and heated to reflux. A pale yellow solution was obtained. After refluxing for 6.5 hours the solution was left in the refrigerator overnight.
- the toluene solution was decanted from some gummy material and evaporated to dryness. Trituration of the residue with dry diethyl ether gave recovered (21) as a solid (414mg). .
- the phosphorane (23) (850mg) was suspended in dry toluene (500ml) and heated under an atmosphere of argon under reflux using a Dean-Stark apparatus to remove water. A clear, pale yellow solution was obtained. After refluxing for 6.5 hours the slightly darker solution was cooled and reduced by evaporation to about 150ml. On storing overnight at 5°, recovered starting material (551mg) was precipitated. The solution was evaporated, and the residue was chromatographed on florisil (200-300 U.S. mesh).
- the p-nitrobenzyl ester (18) (70mg) was dissolved in 30% aqueous dioxan containing 5% Pd/C (90mg) prenyarogenated for twenty minutes].
- the solution was hydrogenated at ambient temperature and pressure for one hour. Examination of the solution by u.v. showed a shift of chromo- phoric absorption of 316 nm and 266 nm for the p-nitrobenzyl ester to 314 nm and 251 nm respectively for the product.
- the solution was treated with one equivalent of NaHC0 3 (14.7mg) in water (2ml) and filtered through keiselguhr.
- the sodium salt (14mg) was dissolved in DMF (2ml) and treated with bromophthalide (10mg). The solution was stirred at RT for 3 hours, the solvent was evaporated, and the residue was dissolved in ethyl acetate and washed with brine (2 x 5ml).
- the phosphorane (d1.5, prepared as in Description 5) (258mg) was dissolved in dry methylene chloride (15ml) containing trifluoracetic acid (0.8ml) and stirred at RT. for ten minutes. The solution was cooled to -70° and ozonised for 15 minutes until a blue colour persisted. Argon was passed through the solution to remove excess ozone and m-chloroperbenzoic acid (90mg) in methylene chloride (5ml) was added. The mixture was allowed to warm up to RT. and stirred overnight. The solvent was evaporated and the residue chromatographed (Kieselgel 60, ⁇ 230 mesh) to yield the phosphorane acid (29) as the trifluoroacetic acid salt.
- the salt was dissolved in methylene chloride and stirred with basic alumina (500m g ) for one hour. The solution was filtered and evaporated to yield the phosphorane-acid (29) as a colourless foam (198 mg) ⁇ max (CHC1 3 ) 1730, 1600cm -1 .
- the phosphorane (30) (218mg) was refluxed in dry toluene (250ml) under argon for 18 hours.
- the solvent was evaporated and the residue chromatographed on florisil (200-300 U.S. mesh) using slight pressure and ethyl acetate/petrol (60-80) as eluant.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB3303777 | 1977-08-06 | ||
GB3303777 | 1977-08-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000828A1 true EP0000828A1 (de) | 1979-02-21 |
EP0000828B1 EP0000828B1 (de) | 1983-03-09 |
Family
ID=10347670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78300231A Expired EP0000828B1 (de) | 1977-08-06 | 1978-08-02 | Synthetische beta-Lactam Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneipräparate |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0000828B1 (de) |
JP (1) | JPS5448786A (de) |
DE (1) | DE2862198D1 (de) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2371542A1 (fr) * | 1976-11-19 | 1978-06-16 | Bayer Ag | Colorants de l'isothiazolanthrone et leur application |
EP0037080A1 (de) * | 1980-03-27 | 1981-10-07 | Merck & Co. Inc. | 4-(3-Carboxy-2-oxopropyl)-azetidino-2-one und Verfahren zu ihrer Herstellung |
EP0037592A2 (de) * | 1978-07-26 | 1981-10-14 | Beecham Group Plc | Beta-lactam-Verbindungen |
EP0001628B1 (de) * | 1977-10-19 | 1984-01-18 | Merck & Co. Inc. | 3,6-Disubstituierte 7-oxo-1-azabicylo-(3.2.0.)-2-hepten-2-carbonsäure, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
US4992542A (en) * | 1984-01-24 | 1991-02-12 | Merck & Co., Inc. | 2-substituted-6-carbadethiapen-2-em-3-carboxylic acids |
EP0499196A1 (de) * | 1991-02-13 | 1992-08-19 | Fujisawa Pharmaceutical Co., Ltd. | Zwischenprodukte und Verfahren zur Herstellung von Carbapenem-Derivaten |
EP0587436A1 (de) * | 1992-09-09 | 1994-03-16 | Sankyo Company Limited | Verfahren zur Herstellung von Carbapenem- und Penemverbindungen und beteiligte Verbindungen in diesem Verfahren |
US5541317A (en) * | 1991-05-31 | 1996-07-30 | Sankyo Company, Limited | Azetidinone compounds useful in the preparation of carbapenem antibiotics and process for preparing carbapenem and penem compounds |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56142260A (en) * | 1980-04-09 | 1981-11-06 | Toyama Chem Co Ltd | 2-azetidinone and its preparation |
JPS56145271A (en) * | 1980-04-11 | 1981-11-11 | Dai Ichi Seiyaku Co Ltd | 2-azetidinone derivative |
JPS57103057A (en) * | 1980-12-19 | 1982-06-26 | Meito Sangyo Kk | Automatic measuring method for hdl-cholesterol and its precipitant |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2371449A1 (fr) * | 1976-11-19 | 1978-06-16 | Merck & Co Inc | Acide 1-carba-2-penem-3-carboxylique |
-
1978
- 1978-08-02 EP EP78300231A patent/EP0000828B1/de not_active Expired
- 1978-08-02 DE DE7878300231T patent/DE2862198D1/de not_active Expired
- 1978-08-07 JP JP9658978A patent/JPS5448786A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2371449A1 (fr) * | 1976-11-19 | 1978-06-16 | Merck & Co Inc | Acide 1-carba-2-penem-3-carboxylique |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2371542A1 (fr) * | 1976-11-19 | 1978-06-16 | Bayer Ag | Colorants de l'isothiazolanthrone et leur application |
EP0001628B1 (de) * | 1977-10-19 | 1984-01-18 | Merck & Co. Inc. | 3,6-Disubstituierte 7-oxo-1-azabicylo-(3.2.0.)-2-hepten-2-carbonsäure, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
EP0038087A2 (de) * | 1978-07-26 | 1981-10-21 | Beecham Group Plc | Beta-Lactam enthaltende Verbindungen, ihre Herstellung und Verwendung |
EP0037592A2 (de) * | 1978-07-26 | 1981-10-14 | Beecham Group Plc | Beta-lactam-Verbindungen |
EP0038087A3 (de) * | 1978-07-26 | 1981-10-28 | Beecham Group Plc | Beta-Lactam enthaltende Verbindungen, ihre Herstellung und Verwendung |
EP0037592A3 (de) * | 1978-07-26 | 1982-03-03 | Beecham Group Plc | Beta-lactam-Verbindungen |
EP0037080A1 (de) * | 1980-03-27 | 1981-10-07 | Merck & Co. Inc. | 4-(3-Carboxy-2-oxopropyl)-azetidino-2-one und Verfahren zu ihrer Herstellung |
US4992542A (en) * | 1984-01-24 | 1991-02-12 | Merck & Co., Inc. | 2-substituted-6-carbadethiapen-2-em-3-carboxylic acids |
EP0499196A1 (de) * | 1991-02-13 | 1992-08-19 | Fujisawa Pharmaceutical Co., Ltd. | Zwischenprodukte und Verfahren zur Herstellung von Carbapenem-Derivaten |
US5306816A (en) * | 1991-02-13 | 1994-04-26 | Fujisawa Pharmaceutical Co., Ltd. | Processes for preparing carbapenem derivatives |
US5541317A (en) * | 1991-05-31 | 1996-07-30 | Sankyo Company, Limited | Azetidinone compounds useful in the preparation of carbapenem antibiotics and process for preparing carbapenem and penem compounds |
US5614624A (en) * | 1991-05-31 | 1997-03-25 | Sankyo Company, Limited | Carbapenem |
US5681951A (en) * | 1991-05-31 | 1997-10-28 | Sankyo Company, Limited | Metal catalyzed displacement process |
US5719275A (en) * | 1991-05-31 | 1998-02-17 | Sankyo Company, Limited | Silyl enol ether alkylation process |
EP0587436A1 (de) * | 1992-09-09 | 1994-03-16 | Sankyo Company Limited | Verfahren zur Herstellung von Carbapenem- und Penemverbindungen und beteiligte Verbindungen in diesem Verfahren |
Also Published As
Publication number | Publication date |
---|---|
EP0000828B1 (de) | 1983-03-09 |
DE2862198D1 (en) | 1983-04-14 |
JPS5448786A (en) | 1979-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4282236A (en) | β-Lactam antibacterial agents, their use in pharmaceutical compositions, and intermediates | |
US4289696A (en) | Polycyclic compounds | |
US4153714A (en) | 3-Thio-5-methyl-7-oxo-1-azabicyclo[3,2,0]hept-2-ene-2-carboxylic acid esters, their production and use | |
US4446146A (en) | β-Lactam containing compounds, their preparation and use | |
EP0000828B1 (de) | Synthetische beta-Lactam Verbindungen, Verfahren zu ihrer Herstellung und diese enthaltende Arzneipräparate | |
US4210661A (en) | Synthetic β-lactam compounds, a process for their preparation and compositions containing them | |
EP0008514B1 (de) | Beta-Lactam-Antibiotika, diese enthaltende Zusammensetzungen und ein Verfahren zu ihrer Herstellung | |
US4155912A (en) | 2-Methylpenem-3-carboxylic acid antibiotics | |
HU196071B (en) | Process for production of carbopenems and medical compounds containing such compositions | |
EP0008888B1 (de) | Antibakterielle Beta-Lactam-Verbindungen, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
EP0238285A2 (de) | 2-Heterocyclylthio-Peneme | |
EP0005349A1 (de) | Alkylcarbapeneme, ihre Herstellung, pharmazeutische Zubereitungen und Zwischenprodukte | |
US4258050A (en) | Antibacterial agents | |
EP0003740B1 (de) | Beta-Lactamantibiotika, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
US4263314A (en) | β-Lactam antibiotics, a process for their preparation and their use in pharmaceutical compositions | |
IE55225B1 (en) | Carbapenem antibiotics | |
US4255441A (en) | β-Lactam antibiotics, a process for their prepaeration and their use in pharmaceutical compositions | |
GB2105329A (en) | Penem-3-carboxylic acid derivatives their preparation and their use as antimicrobial agents | |
EP0033209B1 (de) | Beta-Lactam enthaltende Verbindungen, ihre Herstellung und Verwendung | |
GB2037277A (en) | beta -Lactam antibacterial agents, their use in pharmaceutical compositions, processes for their preparation and intermediates for use in such processes | |
EP0004132A1 (de) | Beta-Lactamester Antibiotika, Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen | |
US4293501A (en) | β-Lactam antibiotics, a process for their preparation and their use in pharmaceutical compositions | |
JPS6187682A (ja) | カルバペネム抗生物質 | |
US4169833A (en) | Novel phosphorane intermediates for use in preparing penem antibiotics | |
KR0167718B1 (ko) | 베타-메틸 카르바페넴 유도체 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB NL |
|
17P | Request for examination filed | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEECHAM GROUP PLC |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): CH DE FR GB NL |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 2862198 Country of ref document: DE Date of ref document: 19830414 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19830722 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19830819 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19830826 Year of fee payment: 6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19830901 Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19840831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19850301 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19850430 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19850501 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19881117 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |